The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study
- PMID: 27877031
- PMCID: PMC5108503
- DOI: 10.2147/COPD.S116750
The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study
Abstract
To investigate the association between inhaled corticosteroid (ICS) exposure patterns and the risk of pneumonia in chronic obstructive pulmonary disease (COPD) patients, we performed a nested case-control study. Between 1998 and 2010, 51,739 patients, including 19,838 cases of pneumonia, were matched to 74,849 control subjects selected from a cohort of COPD patients using ICSs via risk-set sampling of the database constructed by the National Health Research Institutes of Taiwan. After adjusting for covariates, the current use of ICSs was associated with a 25% increase in the risk of pneumonia (odds ratio [OR] =1.25, 95% confidence interval [CI] =1.20-1.30), and there was an increase in the OR with increase in the average daily dosage. Additionally, users of fluticasone/salmeterol, fluticasone, and either fluticasone/salmeterol or fluticasone were more likely to be at a higher risk of pneumonia (OR =1.35, 95% CI =1.28-1.41; OR =1.22, 95% CI =1.10-1.35; and OR =1.33, 95% CI =1.27-1.39, respectively). In contrast, there were no statistically significant associations between the risk of pneumonia and the use of budesonide/formoterol, budesonide, or either budesonide/formoterol or budesonide. In conclusion, ICSs are significantly associated with an increased risk of pneumonia in COPD patients. The effect is prominent for fluticasone-containing ICSs but not for budesonide-containing ICSs.
Keywords: chronic obstructive pulmonary disease; inhaled corticosteroid; pneumonia.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.Int J Chron Obstruct Pulmon Dis. 2017 Oct 19;12:3055-3064. doi: 10.2147/COPD.S143656. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29089754 Free PMC article. Review.
-
Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.Int J Chron Obstruct Pulmon Dis. 2017 Aug 21;12:2477-2485. doi: 10.2147/COPD.S139035. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28860742 Free PMC article.
-
Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.Int J Chron Obstruct Pulmon Dis. 2016 Nov 4;11:2749-2755. doi: 10.2147/COPD.S114554. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27853362 Free PMC article.
-
Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.Int J Chron Obstruct Pulmon Dis. 2016 Sep 21;11:2341-2348. doi: 10.2147/COPD.S115132. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27703344 Free PMC article. Clinical Trial.
-
Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.Pulm Pharmacol Ther. 2015 Feb;30:44-50. doi: 10.1016/j.pupt.2014.10.006. Epub 2014 Nov 6. Pulm Pharmacol Ther. 2015. PMID: 25445928 Review.
Cited by
-
Inhaled corticosteroids in COPD: Personalising the therapeutic choice.Afr J Thorac Crit Care Med. 2018 Apr 3;24(1):10.7196/AJTCCM.2018.v24i1.184. doi: 10.7196/AJTCCM.2018.v24i1.184. eCollection 2018. Afr J Thorac Crit Care Med. 2018. PMID: 34541493 Free PMC article. Review.
-
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.Eur Respir Rev. 2021 Jun 23;30(160):210075. doi: 10.1183/16000617.0075-2021. Print 2021 Jun 30. Eur Respir Rev. 2021. PMID: 34168063 Free PMC article. Review.
-
Response to the Letter to the Editor Regarding "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Response to Letter].Int J Chron Obstruct Pulmon Dis. 2021 May 10;16:1227-1229. doi: 10.2147/COPD.S315195. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34007165 Free PMC article. No abstract available.
-
Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study.Int J Chron Obstruct Pulmon Dis. 2020 Dec 29;15:3397-3406. doi: 10.2147/COPD.S286149. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33402820 Free PMC article.
-
Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies.Int J Chron Obstruct Pulmon Dis. 2020 Nov 11;15:2889-2900. doi: 10.2147/COPD.S269637. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33204085 Free PMC article. Review.
References
-
- Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. - PubMed
-
- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757. - PubMed
-
- Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773. - PubMed
-
- Beran D, Zar HJ, Perrin C, Menezes AM, Burney P, Forum of International Respiratory Societies working group collaboration Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med. 2015;3(2):159–170. - PubMed
-
- Bhatt SP, Wells JM, Dransfield MT. Cardiovascular disease in COPD: a call for action. Lancet Respir Med. 2014;2(10):783–785. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical